The National Institutes of Health has awarded $69.6 million to the UCLA Clinical and Translational Science Institute, a research partnership of UCLA, Cedars-Sinai Medical Center, Charles R. Drew University of Medicine and Science, and the Los Angeles Biomedical Research Institute.
The new five-year grant follows the consortium's initial $83.1 million Clinical and Translational Science Award in 2011, bringing the total support from NIH's National Center for Advancing Translational Sciences to more than $152.7 million.
Both grants support the continued development of the prestigious consortium, one of more than 60 such research partnerships established by the NIH to enhance biomedical research. The consortium accelerates the translation of laboratory discoveries into more effective treatments for patients; actively engages communities in clinical research; and trains future generations of researchers to work across scientific disciplines to improve health. The mission of the UCLA Clinical and Translational Science Institute (CTSI) is to bring biomedical innovations to bear on the greatest health needs of Los Angeles, the largest county in the country, and one of the most diverse.
"The NIH's generous investment is further enabling UCLA and its consortium partners to improve the health of Los Angeles in a meaningful way and to enhance the quality of life in our community," said Dr. John C. Mazziotta, vice chancellor of UCLA Health Sciences and chief executive officer of UCLA Health. "As we go forward and make continued improvements in translating research into better treatments for those diseases that cause the most disability and early deaths in Los Angeles County, our experiences and successes will provide a model for health improvement nationwide."
To date, the CTSI has supported the work of more than 1,600 investigators, including basic scientists, clinicians and population researchers. CTSI infrastructure has supported 40,000 clinical research visits in outpatient, inpatient and community settings.
CTSI-supported researchers have published more than 1,600 scientific articles and been awarded 370 pilot grants, enabling them to generate data that they leveraged into $58 million in additional outside funding.
David Meyer, president and chief executive officer of the Los Angeles Biomedical Research Institute, said that with the renewal of this grant, crucial funding will flow to accelerate the development the next generation of devices, diagnostics and therapies, and to advance the field of precision medicine.
Dr. Steven M. Dubinett, director of the CTSI, Senior Associate Dean for Translational Research and Associate Vice Chancellor for Research at the David Geffen School of Medicine at UCLA, said the CTSI grants allow for the creation of "a borderless clinical and translational research institute that brings UCLA CTSI innovations and resources to bear on the greatest health needs of Los Angeles."
"This funding is helping us develop new means to retain, recruit and empower scientists to work together across disciplines, departments, institutions and geography," Dubinett said.